FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

Min Lu(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Dwaine Rieves(United States Food and Drug Administration), Martin H. Cohen(United States Food and Drug Administration)
American Journal of Hematology
January 20, 2010
10.1002/ajh.21656
Cited by 438

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861